Breaking Finance News

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has been upgraded to Hold in a statement by ValuEngine earlier today.

Boasting a price of $43.55, Pacira Pharmaceuticals Inc (NASDAQ:PCRX) traded -2.11% lower on the day. With the last stock price close down -16.70% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Pacira Pharmaceuticals Inc has recorded a 50-day average of $37.12 and a two hundred day average of $44.48. Volume of trade was up over the average, with 712,550 shares of PCRX changing hands over the typical 691,725

ValuEngine has upgraded Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to Hold in a statement released on Tuesday June 20, 2017.

On 05/05/2017, Mizuho Securities released a statement for Pacira Pharmaceuticals Inc (NASDAQ:PCRX) bumped down the target price from $57.00 to $54.00 that suggested an upside of 0.15%.

Performance Chart

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

With a total market value of $0, Pacira Pharmaceuticals Inc has with a one year low of $29.95 and a one year high of $58.95 .

A total of 9 equity analysts have released a ratings update on PCRX. Five equity analysts rating the company a strong buy, four equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $82.22.

Brief Synopsis About Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.